GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes (Q34041838)

30 July 2017

title

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes (English)

1 reference

30 July 2017

0 references

0 references

2

1 reference

30 July 2017

Bertrand Cariou

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

28 August 2014

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

23

1 reference

30 July 2017

issue

10

1 reference

30 July 2017

page(s)

1441-1448

1 reference

Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Insulin signalling and the regulation of glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Roles of liver innate immune cells in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Thiazolidinediones and PPARγ agonists: time for a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Cellular and molecular mechanisms of metformin: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Fibrates, glitazones, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

PPARdelta regulates glucose metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Roles of PPARs in NAFLD: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Cellular mechanisms of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

The role of hepatokines in metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Harnessing the benefits of PPARβ/δ agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.954034

10.1517/13543784.2014.954034

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference